SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as shareholders anticipate potential FDA developments following reports of leadership turmoil at the agency and increased institutional positioning from major firms like Vanguard. The community is actively discussing the stock's significant short interest and potential catalysts, including global expansion and the anticipated filing decision for Anktiva's label expansion.

Digi Power X, Inc. is a block chain technology company, which engages in crypto currency mining. It focuses on validation through mining, hosting solutions, and blockchain software solutions. It operates through the following segments: Cryptocurrency Mining, Sales of Energy and Electricity, and Colocation Services. The company was founded on February 18, 2017, and is headquartered in Miami, FL.

Digi Power X Inc. - Ordinary Shares (Sub voting)

Digi Power X ($DGXX) is trending as investors rally around its major colocation agreement with Cerebras Systems, viewing it as a critical infrastructure proxy ahead of the upcoming high-profile IPO. The community is actively discussing the stock's transition to an AI-focused data center play and debating the impact of its at-the-market (ATM) equity program as institutional interest grows.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is experiencing heightened volatility and increased trading volume as the community reacts to emerging details about an early-stage hantavirus vaccine program. Investors are actively debating the stock's future, balancing potential pandemic-driven upside against broader biotech sector rotations and upcoming clinical data presentations.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is experiencing an intense rally fueled by structural memory shortages and sustained demand for AI infrastructure, leading to widespread community debate over whether the stock is undergoing a long-term rerating or forming a speculative bubble. Investors are actively discussing the impact of supply bottlenecks, potential production strikes, and the company's role as a critical component supplier in the growing AI hardware ecosystem.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

DXYZ is seeing increased investor activity driven by anticipation of upcoming SpaceX and Anthropic IPOs, as the fund provides a rare opportunity for retail exposure to these private tech unicorns. While the community is actively debating the fund's valuation premium relative to its net asset value, bullish sentiment remains centered on the massive potential of its portfolio holdings as market participants look for long-term growth before the highly anticipated public listings.

Barrick Mining Corp. engages in the production and sale of gold, copper, and related activities. It also provides exploration and mining development. It operates through the following business segments: Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, Bulyanhulu, and Other Mines. The company was founded by Peter D. Munk in 1983 and is headquartered in Toronto, Canada.

Barrick Mining Corp.

Barrick Mining Corp

Barrick Mining is trending as investors pivot toward its upcoming earnings report and the proposed IPO of its North American gold assets, aiming to unlock significant shareholder value. Community discussions are heavily focused on the company's strong dividend growth, record gold price environments, and the strategic importance of its massive Reko Diq copper-gold project.

High-Trend International Group is a holding company. It engages in shipping decarbonization and carbon asset management platforms. The company was founded in 2021 and is headquartered in Singapore.

High-Trend International Group. - Ordinary Shares - Class A

HTCO is seeing significant volatility driven by a massive short squeeze and retail speculation, with community sentiment split between those capitalizing on the rapid upward momentum and others warning of a typical pump-and-dump cycle. Traders are closely monitoring low volume levels and frequent trading halts while debating whether the stock will sustain its parabolic gains or succumb to a sharp reversal.

Babcock & Wilcox Enterprises, Inc. engages in the provision of fossil and renewable power generation and environmental equipment. It operates through the B&W segment. The company was founded by George H. Babcock, Stephen Wilcox, Jr., and Joseph P. Manton in 1856 and is headquartered in Akron, OH.

Babcock & Wilcox Enterprises Inc

Babcock & Wilcox Enterprises is facing high volatility as investors weigh solid earnings results and a multi-billion dollar pipeline against short-seller reports challenging its flagship AI power contracts. While the community is actively debating the legitimacy of these short-seller claims and the potential for a recovery, bulls are focused on the company's expanding project backlog and management's ongoing strategic growth in the data center energy sector.

NovaChargeX Coin (NCX) is an Ethereum-based ERC-20 token connected to NovaChargeX LLC, a clean-energy company developing patented hybrid regenerative power systems designed to deliver continuous, grid-independent electricity. The token serves as the on-chain entry point to the NovaChargeX ecosystem, linking blockchain participants to a real-world infrastructure project focused on supplying 24/7 power to AI data centers, industrial facilities, and other operations that cannot tolerate downtime. NCX is positioned in the real-world asset (RWA) and clean-energy infrastructure category. The parent company has been recognized by the World Future Awards 2025 for Best Hybrid Regenerative Clean Energy System and has received coverage from Al Arabiya English, SolarQuarter, and Reuters. The token contract is deployed on Ethereum mainnet, ownership has been renounced, and a third-party security audit has been completed.

NovaChargeX Coin

NovaChargeX is gaining traction as investors highlight its positioning at the intersection of clean energy infrastructure, real-world assets, and AI power demand. Community members are actively monitoring the project for its low-cap profile and patented energy technology, viewing it as an early-stage alternative to established market narratives.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after reporting a positive final pre-BLA meeting with the FDA, which solidified the development path for its HS treatment and reinforced expectations for a potentially best-in-class label. Investors are actively discussing the upcoming 52-week clinical data readout and evaluating the stock's potential for a significant re-rating as regulatory de-risking milestones are met.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

iTeos Therapeutics (ITOS) Upgraded to Buy: Here's What You Should Know

Shares of biopharmaceutical company iTeos Therapeutics, Inc. (ITOS) traded 20% higher on Wednesday morning after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/05/28/3089457/0/en/iTeos-Therapeutics-Announces-Its-Intention-to-Wind-Down-Operations.html">announced</a> its intent to wind down operations and explore asset sales.iTeos said it decided to wind down operations as part of a review of strategic alternatives aimed at maximizing shareholder value.The Board of Directors now intends to focus on leveraging the company’s cash balance to deliver near-term value to shareholders, including any proceeds from the potential sale of the company’s intellectual property and assets.iTeos ended the first quarter of 2025 with cash and investments of $624.3 million. Last month, the firm had said that it expects its cash balance to provide a runway through 2027.However, earlier this month, iTeos decided to <a href="https://stocktwits.com/news-articles/markets/equity/iteos-gsk-end-collaboration-on-experimental-cancer-therapy/chi8V5tRbZi">terminate</a> its collaboration with British pharmaceutical major GSK Plc for the development of experimental cancer therapy Belrestotug.The two companies were working together assessing the Belrestotug + Dostarlimab doublet in previously untreated, unresectable, locally advanced or metastatic PD-L1 high non-small cell lung cancer.However, data from a Phase 2 study did not show improvements in progression-free survival with the combination compared to Dostarlimab monotherapy, and the companies subsequently decided to terminate the program and end the collaboration.iTeos CEO Michel Detheux had said the company is “truly disappointed” by the trial results and is taking “immediate steps” to preserve capital. &nbsp;On Stocktwits, retail sentiment around ITOS jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/67;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_28_at_11_05_44_AM_png_7ce0e324ab.webp" alt="ITOS's Sentiment Meter and Message Volume as of 11:05 a.m. ET on May 28, 2025 | Source: Stocktwits " width="626" height="67"><figcaption>ITOS's Sentiment Meter and Message Volume as of 11:05 a.m. ET on May 28, 2025 | Source: Stocktwits&nbsp;</figcaption></figure>A Stocktwits user expressed optimism about the company’s decision to halt operations.<stembedurl>https://stocktwits.com/BullDriven/message/616043049</stembedurl><a href="https://stocktwits.com/symbol/ITOS">ITOS stock </a>is up approximately 29% this year but down by more than 40% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/candel-therapeutics-gets-rmat-designation-for-prostate-cancer-therapy/ch0om35Rbs0">Candel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy: Retail Considers It Good Long-Term Buy</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

iTeos Therapeutics To Wind Down Operations, Explores Asset Sale: Retail Believes It’s ‘Worth More Selling It Off’

The company decided to wind down operations as part of a review of strategic alternatives aimed at maximizing shareholder value after its collaboration with GSK plc ended. 

Equity

GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug

Shares of iTeos Therapeutics, Inc. (ITOS) rocketed 20% on Tuesday morning after the company announced it has decided to terminate its collaboration with British pharmaceutical major GSK Plc for the development of its experimental cancer therapy Belrestotug.The two companies were working together assessing the Belrestotug + Dostarlimab doublet in previously untreated, unresectable, locally advanced or metastatic PD-L1 high non-small cell lung cancer.However, data from a Phase 2 study did not show improvements in progression-free survival with the combination compared to Dostarlimab monotherapy. Hence, the two companies have decided to end the collaboration and terminate the program.iTeos <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.iteostherapeutics.com/news-releases/news-release-details/iteos-reports-topline-interim-results-galaxies-lung-201-study">also</a> ended new enrollment for a phase 3 trial of the combination.GSK is communicating with investigators, institutional review boards, ethics committees, and health authorities about next steps for the appropriate management of currently enrolled patients, iTeos said.iTeos CEO Michel Detheux said the company is “truly disappointed” by the trial results. The firm is taking “immediate steps” to preserve capital and maximise shareholder value and has engaged TD Cowen to advise on the process.“...given current market conditions and our appreciation of the responsibility to our valued shareholders, we believe the best path forward is to promptly evaluate a full range of strategic alternatives to unlock the value of our assets,” Detheux said, while adding that the company has a strong balance sheet to enable it to pursue opportunities.On Stocktwits, retail sentiment around ITOS jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:627/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_13_at_9_51_08_AM_png_54cf65be0f.webp" alt="ITOS's Sentiment Meter and Message Volume as of 9:45 a.m. ET on May 13, 2025 | Source: Stocktwits" width="627" height="62"><figcaption>ITOS's Sentiment Meter and Message Volume as of 9:45 a.m. ET on May 13, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/ITOS">ITOS stock</a> is up by about 5% this year but has declined by about 52% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/vehicle-prices-rose-in-april-after-trump-tariffs/chi8mIbRbZg">Cadillac, Tesla, GMC Vehicles Get More Expensive In April After Trump Tariffs, Shows Data</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

iTeos, GSK End Collaboration On Experimental Cancer Therapy Development: But Retail’s Extremely Bullish

The two companies worked together to assess the Belrestotug + Dostarlimab doublet in treating a specific type of lung cancer.

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

ITeos Therapeutics Inc

Up > 1%

Flat +/- 1%

Down > 1%

Where does the $SPY finish next week vs. Friday’s close?

ITOS
ITeos Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Poll

Latest ITOS News

ITOSITeos Therapeutics Inc